Can Amphastar Pharmaceuticals Maintain Its Momentum and Outperform the Market?

Momentum investing is a strategy that involves following the recent trend of a stock, either in an upward or downward direction. In the case of a long-term approach, investors typically aim to "buy high and sell even higher." The key to this methodology lies in taking advantage of a stock's price trends, as once a stock establishes a clear path, it is likely to continue moving in that direction. The goal is to make timely and profitable trades based on these trends.

Identifying momentum in stocks can be challenging, as there is ongoing debate regarding the best metrics to focus on. However, the Zacks Momentum Style Score, which is part of the Zacks Style Scores, helps address this issue by providing a comprehensive assessment.

Let's take a closer look at Amphastar Pharmaceuticals (AMPH), a specialty pharmaceutical company that currently holds a Momentum Style Score of A. We will also discuss some of the main drivers behind the Momentum Style Score, such as price change and earnings estimate revisions.

It is important to note that Style Scores complement the Zacks Rank, a stock rating system with a strong track record of outperformance. Currently, Amphastar Pharmaceuticals holds a Zacks Rank of #1 (Strong Buy). Research has shown that stocks with Zacks Rank #1 and #2 (Buy), along with Style Scores of A or B, tend to outperform the market over the following one-month period.

To determine if AMPH is a promising momentum pick, we need to examine several Momentum Style factors to assess the strength of this specialty pharmaceutical company.

A useful benchmark for momentum is to analyze a stock's short-term price activity, as it reflects current market interest and the balance between buyers and sellers. Additionally, comparing a stock to its industry can identify the top performers in a specific sector.

Over the past week, AMPH shares have gained 1.53%, outperforming the flat performance of the Zacks Medical - Generic Drugs industry during the same period. Looking at a longer time frame, the stock has shown positive momentum, with a monthly price change of 6.79% compared to the industry's 5.86% performance.

While any stock can experience price increases, consistent outperformance is a hallmark of a true winner. Therefore, considering longer-term price metrics, such as performance over the past three months or year, can be valuable. In the last quarter, Amphastar Pharmaceuticals' shares have risen by an impressive 31.07%, and over the past year, they have surged by 120.74%. In contrast, the S&P 500 has posted gains of only 11.67% and 25.85% during the same respective periods.

Investors should also pay attention to AMPH's average 20-day trading volume, as volume serves as a useful indicator in many ways. The 20-day average establishes a baseline for price-to-volume analysis: a rising stock with above-average volume is typically a bullish sign, while a declining stock accompanied by above-average volume is usually bearish. Currently, AMPH has an average trading volume of 440,360 shares over the last 20 days.

The Zacks Momentum Style Score also takes into account trends in earnings estimate revisions, which are an integral part of the Zacks Rank methodology. Positive estimate revision trends often indicate promising prospects for a stock, and AMPH has demonstrated such trends recently.

Over the past two months, two earnings estimates for the full year have moved higher, with none moving lower. These upward revisions have contributed to an increase in AMPH's consensus estimate, which has risen from $2.72 to $3.21 in the past 60 days. Looking ahead to the next fiscal year, two estimates have moved upwards, while there have been no downward revisions during the same period.

In conclusion, considering the factors discussed, it is not surprising that Amphastar Pharmaceuticals is rated as a #1 (Strong Buy) stock and boasts a Momentum Score of A. If you are searching for a potential winner that could soar in the near term, Amphastar Pharmaceuticals should be on your radar.